The search for diabetes medications that help lower blood glucose levels without adding risks to heart health has been going on for years. Ever since studies linked the popular diabetes drug rosiglitazone (Avandia) with greater heart attack risks about 10 years ago, researchers have been developing a new generation of medications to take its place. Two new drugs have emerged from clinical trials with encouraging results. Empagliflozin and liraglutide have both been shown to reduce the risk of cardiovascular death, while effectively helping to lower blood glucose levels.
To continue reading this article or issue you must be a paid subscriber.
Sign in
